BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32081560)

  • 21. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
    BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study.
    Spagnuolo M; Costantini M; Ferriero M; Varmi M; Sperduti I; Regazzo G; Cicchillitti L; Díaz Méndez AB; Cigliana G; Pompeo V; Russo A; Laquintana V; Mastroianni R; Piaggio G; Anceschi U; Brassetti A; Bove A; Tuderti G; Flammia RS; Gallucci M; Simone G; Rizzo MG
    J Exp Clin Cancer Res; 2020 Apr; 39(1):68. PubMed ID: 32303246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of DNA methylation in promoter regions of hTERT, TWIST1, VIM and NID2 genes in Moroccan bladder cancer patients.
    El Azzouzi M; El Ahanidi H; Hafidi Alaoui C; Chaoui I; Benbacer L; Tetou M; Hassan I; Bensaid M; Oukabli M; Ameur A; Al Bouzidi A; El Mzibri M; Attaleb M
    Cancer Genet; 2022 Jan; 260-261():41-45. PubMed ID: 34922269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer.
    Scher MB; Elbaum MB; Mogilevkin Y; Hilbert DW; Mydlo JH; Sidi AA; Adelson ME; Mordechai E; Trama JP
    J Urol; 2012 Dec; 188(6):2101-7. PubMed ID: 23083854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A two-gene methylation signature for the diagnosis of bladder cancer in urine.
    Bosschieter J; Nieuwenhuijzen JA; Hentschel A; van Splunter AP; Segerink LI; Vis AN; Wilting SM; Lissenberg-Witte BI; A van Moorselaar RJ; Steenbergen RD
    Epigenomics; 2019 Feb; 11(3):337-347. PubMed ID: 30706728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer.
    Eissa S; Swellam M; El-Khouly IM; Kassim SK; Shehata H; Mansour A; Esmat M; Nossier AI; Hamdy MA; Awad NM; El-Ahmady O
    Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1657-64. PubMed ID: 21680534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study.
    Ribal MJ; Mengual L; Lozano JJ; Ingelmo-Torres M; Palou J; Rodríguez-Faba O; Witjes JA; Van der Heijden AG; Medina R; Conde JM; Marberger M; Schmidbauer J; Fernández PL; Alcaraz A
    Eur J Cancer; 2016 Feb; 54():131-138. PubMed ID: 26761785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes.
    Pietrusiński M; Kȩpczyński Ƚ; Jȩdrzejczyk A; Borkowska E; Traczyk-Borszyńska M; Constantinou M; Kaƚużewski B; Borowiec M
    Cancer Biomark; 2017; 18(1):47-59. PubMed ID: 27814275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved Noninvasive Bladder Cancer Diagnosis using Urine Sediments and Novel DNA Methylation Biomarker Panels.
    Wang K; Tian Y; Xu H
    Clin Lab; 2016; 62(3):327-36. PubMed ID: 27156320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine.
    Maldonado L; Brait M; Michailidi C; Munari E; Driscoll T; Schultz L; Bivalacqua T; Schoenberg M; Sidransky D; Netto GJ; Hoque MO
    Oncotarget; 2014 Jul; 5(14):5218-33. PubMed ID: 24980822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence.
    Su SF; de Castro Abreu AL; Chihara Y; Tsai Y; Andreu-Vieyra C; Daneshmand S; Skinner EC; Jones PA; Siegmund KD; Liang G
    Clin Cancer Res; 2014 Apr; 20(7):1978-89. PubMed ID: 24691641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical performance and utility of a NNMT-based urine test for bladder cancer.
    Pozzi V; Di Ruscio G; Sartini D; Campagna R; Seta R; Fulvi P; Vici A; Milanese G; Brandoni G; Galosi AB; Montironi R; Cecati M; Emanuelli M
    Int J Biol Markers; 2018 Jan; 33(1):94-101. PubMed ID: 29148015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer.
    Urquidi V; Goodison S; Ross S; Chang M; Dai Y; Rosser CJ
    J Urol; 2012 Dec; 188(6):2377-83. PubMed ID: 23088986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
    Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
    BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary markers in the everyday diagnosis of bladder cancer.
    Dal Moro F; Valotto C; Guttilla A; Zattoni F
    Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
    Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
    Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and validation of methylated PENK gene for early detection of bladder cancer using urine DNA.
    Oh TJ; Lim E; Bang BR; Lee JJ; Na YG; Shin JH; Lim JS; Song KH; An S
    BMC Cancer; 2022 Nov; 22(1):1195. PubMed ID: 36403035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.